Skip to main content

A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation.

Publication ,  Journal Article
Wisler, JW; Becker, RC
Published in: Crit Pathw Cardiol
June 2012

Oral anticoagulation with vitamin K antagonists has served as the primary treatment for the prevention of stroke and systemic embolization in patients with atrial fibrillation (AF) for decades. Over the past several years, multiple novel oral anticoagulants targeting key mediators of coagulation, including thrombin and factor Xa, have been developed. Specifically, agents targeting thrombin (dabigatran) and factor Xa (apixaban and rivaroxaban) have either reached late stages of clinical development (apixaban) or have received approval (dabigatran, rivaroxaban) by the US Food and Drug Administration for use in patients with nonvalvular AF. The promising results derived from large-scale clinical trials with these agents compared to warfarin expand the available therapeutic options for the prevention of stroke and systemic embolization in this rapidly increasing patient population. Here we present a general guidance pathway for the initiation and selection of oral anticoagulants in patients with AF.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Crit Pathw Cardiol

DOI

EISSN

1535-2811

Publication Date

June 2012

Volume

11

Issue

2

Start / End Page

55 / 61

Location

United States

Related Subject Headings

  • Stroke
  • Humans
  • Factor Xa Inhibitors
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Antithrombins
  • Anticoagulants
  • 4203 Health services and systems
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wisler, J. W., & Becker, R. C. (2012). A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation. Crit Pathw Cardiol, 11(2), 55–61. https://doi.org/10.1097/HPC.0b013e31825298ef
Wisler, James W., and Richard C. Becker. “A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation.Crit Pathw Cardiol 11, no. 2 (June 2012): 55–61. https://doi.org/10.1097/HPC.0b013e31825298ef.
Wisler, James W., and Richard C. Becker. “A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation.Crit Pathw Cardiol, vol. 11, no. 2, June 2012, pp. 55–61. Pubmed, doi:10.1097/HPC.0b013e31825298ef.

Published In

Crit Pathw Cardiol

DOI

EISSN

1535-2811

Publication Date

June 2012

Volume

11

Issue

2

Start / End Page

55 / 61

Location

United States

Related Subject Headings

  • Stroke
  • Humans
  • Factor Xa Inhibitors
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Antithrombins
  • Anticoagulants
  • 4203 Health services and systems
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology